Special Issue

Molecular Biology and Precision Medicine of Lung Cancer

Message from the Guest Editors

Lung cancer is a leading cause of cancer-related mortality worldwide. Upon diagnosis, 50% of patients have distant metastases with a 5-year survival rate that is lower than 5%. Most lung cancer patients are diagnosed at an advanced stage, meaning salvage therapy is recommended. Platinum-based chemotherapy is a standard therapy for advanced stage lung cancer but has only been proven to have modest clinical efficacy. Many new target therapies have been developed that have been proven to have better clinical efficacy compared with standard platinum-based chemotherapy. For example, several large-scale phase three clinical trials have shown that a tyrosine kinase inhibitor (TKI) received by lung cancer patients harboring susceptible epidermal growth factor receptor (EGFR) mutations had better clinical efficacy than platinumbased chemotherapy, as determined by the overall response rate, progression free survival (PFS) and quality of life. In this Special Issue on "The Biology and Management of Lung Cancer", we would like to gather high-quality original research or review articles on lung cancer.

Guest Editors

Prof. Dr. Chih-Jen Yang

- Division of Pulmonary and Critical Care Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
- School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
- 3. Lung Cancer Team, Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Dr. Hsiang-Hao Chuang

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, Taiwan

Deadline for manuscript submissions

closed (15 December 2022)



an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/102646

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).